home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2880.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
39 lines
Document 2880
DOCN M94A2880
TI Vesnarinone; a preliminary therapeutic approach in HIV-1 infection.
DT 9412
AU Maruyama Y; Kobayashi N; Maruyama I; Osame M; Third Department of
Internal Medicine, School of Medicine,; Kagoshima University, Japan.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):203 (abstract no. PB0241). Unique
Identifier : AIDSLINE ICA10/94369695
AB OBJECTIVE: To investigate the efficacy and safety of a new
anti-retroviral agent, vesnarinone. METHODS: Studied were nine patients
with HIV-1 infected hemophiliacs (30.3 +/- 5.6 years old, male, AIDS 5,
ARC 3, AC 1). Eight patients received AZT and/or ddI in combination with
vesnarinone. One patient received monotherapy with vesnarinone. All
patients started to receive 60 mg daily oral vesnarinone. We evaluated
peripheral blood cells, CD4 counts, HIV-1 proviral DNA and their
clinical symptoms. RESULTS: There was no worsening of the HIV-1
infection. CD 4 counts increased in 2 patients and HIV-1 proviral DNA
decreased in 4 patients, 1-2 months after vesnarinone treatment. No
patient had adverse drug reactions. DISCUSSION AND CONCLUSION:
Vesnarinone inhibits production of HIV-1 and decreases the production of
TNF-a and IL-6 in ex-vivo study (I. Maruyama, et al. BBRC 195, 1264,
1993). Our preliminary data suggested that this may be a potentially
effective anti-retroviral agent which is less toxic compared with AZT or
ddI. To verify the efficacy of vesnarinone with anti-viral activity and
cytokine levels, a nation-wide multicentric monotherapy trial has been
started in Japan.
DE Antiviral Agents/ADVERSE EFFECTS/*PHARMACOLOGY Didanosine/THERAPEUTIC
USE Drug Therapy, Combination DNA, Viral/BLOOD
Hemophilia/COMPLICATIONS Human HIV Infections/COMPLICATIONS/*DRUG
THERAPY *HIV-1/ISOLATION & PURIF Leukocyte Count Male
Proviruses/ISOLATION & PURIF Quinolines/ADVERSE EFFECTS/*PHARMACOLOGY
Safety Treatment Outcome T4 Lymphocytes Viremia/DRUG THERAPY
Zidovudine/THERAPEUTIC USE CLINICAL TRIAL MEETING ABSTRACT
MULTICENTER STUDY
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).